

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10560069
	Filing Date	2005-12-09
	First Named Inventor	Stephen John KENT
	Art Unit	1644
	Examiner Name	Amy E. Juedes
	Attorney Docket Number	00704.8010.US00

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	PIOT, P., et al., The Global Impact of HIV/AIDS, Nature, (2001), 410(6831): pp 968-73.	<input type="checkbox"/>
	2	UNAIDS, Global Estimates of HIV/AIDS Epidemic as of end (2002), 2003, UNAIDS.	<input type="checkbox"/>
	3	BORROW, P., et al., Virus-Specific CD8+ Cytotoxic T-Lymphocyte Activity Associated....., J Virol, (1994), 68(9): pp 6103-10.	<input type="checkbox"/>
	4	KOUP, R. A., et al., Temporal Association of Cellular Immune Responses with the Initial Control of Viremia....., J Virol, (1994) 68(7): pp 4650-5.	<input type="checkbox"/>
	5	MUSEY, L., et al., Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human....., N. Engl J Med, (1997), 337(18): pp 1267-74.	<input type="checkbox"/>
	6	OGG, G. S., et al., Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load....., Science, (1998), 279 (5359): pp 2103-6.	<input type="checkbox"/>
	7	CARMICHAEL, A., et al., Quantitative Analysis of the Human Immunodeficiency Virus Type 1...., J Exp Med, (1993), 177(2): pp 249-56.	<input type="checkbox"/>
	8	RINALDO, C., et al., High Levels of Anti-Human Immunodeficiency Virus Type 1 (HIV-1)...., J Virol, (1995); 69(9): pp 5838-42.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	00704.8010 US00

9	HAY, C. M., et al., Lack of Viral Escape and Defective In Vivo Activation of Human Immunodeficiency. ..., J Virol, (1999), 73(7): pp 5509-19.	<input type="checkbox"/>
10	JOHNSON, P. R., et al., Inactivated Whole SIV Vaccine in Macaques: Evaluation of Protective Efficacy..., AIDS Research and Human Retroviruses (1992) 8(8): pp 1501-5.	<input type="checkbox"/>
11	CRANAGE, M. P., et al., Studies on the Specificity of the Vaccine Effect Elicited by Inactivated Simian..., AIDS Research and Human Retroviruses, (1993), 9(1): pp 13-22.	<input type="checkbox"/>
12	LUKE, W., et al., Simian Immunodeficiency Virus (SIV) gp130 Oligomers Protect Rhesus Macaques..., (1996), 216(2): pp 444-50.	<input type="checkbox"/>
13	MOOIJ, P., et al., A Clinically Relevant HIV-1 subunit Vaccine Protects Rhesus Macaques From In Vivo. ..., (1998), 12 (5): pp F15-22.	<input type="checkbox"/>
14	VaxGen, I., VaxGen Announces Initial Results of its Phase III AIDS Vaccine Trial. (2003) PR Newswire.	<input type="checkbox"/>
15	KENT, S. J., Vaccination with Attenuated Simian Immunodeficiency Virus by DNA Inoculation, J Virol, (2001), 75(23): pp 11930-4.	<input type="checkbox"/>
16	KENT, S. J., et al., Enhanced T-Cell Immunogenicity of Protective Efficacy of a Human Immunodeficiency Virus..., J Virol, (1998), 72(12): pp 10180-8.	<input type="checkbox"/>
17	SANTRA, S., et al., Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response..., J Virol, (2002), 76(12): pp 6376-81.	<input type="checkbox"/>
18	ESTCOURT, M. J., et al, Prime-boost Immunization Generates a High Frequency, High-avidity CD8+..., Int Immunol, (2002), 14(1): pp 31-7.	<input type="checkbox"/>
19	MARZO, A. L., et al., Tumor-Specific CD4+ T Cells Have a Major "Post-Licensing" Role in CTL Mediated..., J Immunol, (2000), 165(11): pp 6047-55.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	00704.8010.US00

20	NELSON, D. J., et al., Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective..., J Immunol (2001), 166(9): pp 5557-66.	<input type="checkbox"/>
21	RITCHIE, D. S., et al., Dendritic Cell Elimination as an Assay of Cytotoxic T Lymphocyte..., J Immunol Methods, (2000), 246(1-2): pp 109-17.	<input type="checkbox"/>
22	CARBONE, F. R., et al., Induction of Ovalbumin-Specific Cytotoxic T Cells By In Vivo Peptide..., J Exp Med, (1989), 169(3): pp 603-12.	<input type="checkbox"/>
23	CARBONE, F. R., et al., Induction of Cytotoxic T lymphocytes By Primary In Vivo Stimulation with Peptides..., J Exp Med, (1988), 167(6): pp 1767-79.	<input type="checkbox"/>
24	KAST, W. M., et al, Protection Against Lethal Sendai Virus Infection by In Vivo Priming of Virus-Specific..., Proc Natl Acad Sci USA, (1991), 88(6): pp 2283-7.	<input type="checkbox"/>
25	SCHULZ, M., et al, Peptide-Induced Antiviral Protection by Cytotoxic T Cells, Proc Natl Acad Sci USA, (1991), 88(3): pp 991-3.	<input type="checkbox"/>
26	FELTKAMP, M. C., et al., Vaccination with Cytotoxic T Lymphocyte Epitope-Containing Peptide Protects.., Eur J Immunol, (1993), 23(9): pp 2242-9.	<input type="checkbox"/>
27	CELLUZZI, C. M., et al., Peptide-Pulsed Dendritic Cells Induce Antigen-Specific, CTL-Mediated Protective..., J Exp Med, (1996), 183(1): pp 283-7.	<input type="checkbox"/>
28	KEARNEY, E. R., et al, Visualization of Peptide-Specific T Cell Immunity and Peripheral Tolerance..., Immunity, (1994), 1(4): pp 327-39.	<input type="checkbox"/>
29	AICHELE, P., et al., T Cell Priming Versus T Cell Tolerance Induced By Synthetic Peptides, J Exp Med, (1995), 182 (1): pp 281-6.	<input type="checkbox"/>
30	TOES, R. E., et al., Peptide Vaccination Can Lead to Enhanced Tumor Growth Through Specific T-Cell.., J Immunol, (1996), 156(10): pp 3911-8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	00704.8010.US00

31	TOES, R. E., et al., Enhanced Tumor Outgrowth after Peptide Vaccination, Proc Natl Acad Sci USA, (1996), 93(15): pp 7855-60.	<input type="checkbox"/>
32	DALE, C. J., et al, Chimeric Human Papilloma Virus-Simian/Human Immunodeficiency Virus Virus-Like-Particle..., Virology, (2002), 301(1): pp 176-87.	<input type="checkbox"/>
33	JIN, X., et al., Dramatic Rise in Plasma Viremia After CD8+ T Cell Depletion in Simian ..., J Exp Med, (1999), 189(6): pp 991-8	<input type="checkbox"/>
34	CARBONE, F. R., et al., Class I-Restricted Processing and Presentation of Exogenous Cell-Associated..., J Exp Med, (1990), 171(2): pp 377-87.	<input type="checkbox"/>
35	LARSSON, M., et al., Efficiency of Cross Presentation of Vaccinia Virus-Derived Antigens by Human..., Eur J Immunol, (2001), 31(12): pp 3432-42.	<input type="checkbox"/>
36	CHEN, Q., et al., A Direct Comparison of Cytolytic T-Lymphocyte Responses to Melan-A Peptides in Vitro..., Melanoma Res, (2000), 10(1): pp 16-25.	<input type="checkbox"/>
37	LU, W., et al., Therapeutic Dendritic-Cell Vaccine for Simian AIDS, Nat Med, (2003), 9(1): pp 27-32.	<input type="checkbox"/>
38	POSPISILOV, D., et al., Generation of Functional Dendritic Cells For Potential Use in the Treatment..., Cancer Immunol Immunother, (2002), 51(2): pp 72-8.	<input type="checkbox"/>
39	MELIEF, C. J., et al., Effective Therapeutic Anticancer Vaccines Based on Precision Guiding of Cytolytic ..., Immunol Rev, (2002), 188(1): pp 177-82.	<input type="checkbox"/>
40	MEHLHOP, E., et al., Enhanced In Vitro Stimulation of Rhesus Macaque Dendritic Cell for Activation..., J Immunol Methods, (2002), 260(1-2): pp 219-34.	<input type="checkbox"/>
41	SAPP, M., et al., Dendritic Cells Generated from Blood Monocytes of HIV-1 Patients are Not Infected and act..., Immunol Lett, (1999), 66(1-3): pp 121-8.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10560069
Filing Date	2005-12-09
First Named Inventor	Stephen John KENT
Art Unit	1644
Examiner Name	Amy E. Juedes
Attorney Docket Number	00704.8010.US00

42	CHOUGNET, C., et al., Normal Immune Function of Monocyte-Derived Dendritic Cells from HIV-Infected Individuals....., J Immunol, (1999), 163(3): pp 1666-73.	<input type="checkbox"/>
43		<input type="checkbox"/>
44		<input type="checkbox"/>
45		<input type="checkbox"/>
46		<input type="checkbox"/>
47		<input type="checkbox"/>
48		<input type="checkbox"/>
49		<input type="checkbox"/>
50		<input type="checkbox"/>
51		<input type="checkbox"/>
52		<input type="checkbox"/>